gilaxia / iStockphoto.com
BACIT, a former fund of funds, has combined with life sciences investment company Syncona to form a new investment vehicle using the latter’s name. LSIPR speaks to Arabella Cecil, one of the co-founders of BACIT, about the new company’s vision.
In 2012, there was a gap in the life sciences investment market.
Charities and researchers were faced with living hand to mouth—they received lump sums but were not sure whether they could spend the money and, if so, at what rate, because they didn’t know when the next payment was coming in.
That’s according to Arabella Cecil, a co-founder of what was, until December last year, investment fund BACIT, which is now known as Syncona after a combination of the businesses.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Arabella Cecil, Syncona, LSIPR 50 2017, researchers, BACIT, Syncona, life sciences, researchers,
